- Achaogen (NASDAQ:AKAO) appoints Ian Friedland, M.D., as its Chief Medical Officer. He joins the company from Cubist Pharmaceuticals (NASDAQ:CBST) where he was VP of Clinical Development. Dr. Friedland will be responsible for leading the Phase 3 clinical trial for plazomicin, the firm's lead product for serious bacterial infections due to MDR Enterobacteriaceae.
From other sites
at Benzinga.com (Jan 8, 2015)
at MarketWatch.com (Oct 3, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs